# LEGEND-T2DM Evidence Dissemination Summary

Target: **sitagliptin**, Comparator: **dapagliflozin** Outcome: **Diarrhea** Subgroup: **All**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	40,426	32,776	967	29.50
Clinformatics	20,601	15,678	699	44.58
DA Germany	17,295	18,187	41	2.25
LDP France	-	-	-	-
MDCD	5,206	3,451	184	53.32
MDCR	6,315	5,020	199	39.64
Open Claims	539,284	472,190	9,210	19.50
Optum EHR	50,063	23,126	857	37.06
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)

What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)